Enhabit (NYSE:EHAB) Posts Earnings Results, Misses Expectations By $0.03 EPS

Enhabit (NYSE:EHAB) announced its quarterly earnings data on Wednesday. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.03), Zacks reports. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. Enhabit updated its FY 2025 guidance to 0.410-0.510 EPS.

Enhabit Stock Up 1.0 %

EHAB traded up $0.08 during trading on Wednesday, reaching $8.55. The stock had a trading volume of 306,020 shares, compared to its average volume of 276,512. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $430.13 million, a price-to-earnings ratio of -3.69 and a beta of 1.83. The stock’s 50 day moving average is $8.16 and its two-hundred day moving average is $7.90. Enhabit has a one year low of $6.85 and a one year high of $11.74.

Insider Buying and Selling

In other news, Director Jeffrey Bolton acquired 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $8.69 per share, for a total transaction of $34,760.00. Following the acquisition, the director now directly owns 98,144 shares in the company, valued at approximately $852,871.36. The trade was a 4.25 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Stuart M. Mcguigan bought 15,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were acquired at an average price of $8.81 per share, for a total transaction of $132,150.00. Following the completion of the purchase, the director now owns 46,810 shares in the company, valued at approximately $412,396.10. The trade was a 47.15 % increase in their position. The disclosure for this purchase can be found here. 1.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Jefferies Financial Group upgraded Enhabit from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $8.25 to $9.50 in a report on Monday, December 9th. Leerink Partners reaffirmed a “market perform” rating and set a $8.00 target price (down previously from $8.50) on shares of Enhabit in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.75.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.